Variable | LVEDP ≤ 16 mmHg (n = 18) | LVEDP > 16 mmHg (n = 31) | P | validation group (n = 339) |
---|---|---|---|---|
Baseline Characteristics | ||||
Female (n (%)) | 4 (22%) | 11 (30.6%) | 0.332 | 172 (50.7%) |
Age(year) | 64 ± 2 | 63 ± 2 | 0.563 | 63 ± 1 |
HR (beats/min) | 63 ± 2 | 68 ± 2 | 0.144 | 72 ± 1 |
BMI(kg/m2) | 24.1 ± 0.7 | 24.6 ± 0.5 | 0.641 | 24.1 ± 0.2 |
Medical history, n (%) | ||||
Hypertension | 11 (61%) | 26 (83%) | 0.149 | 198 (58.4%) |
CAD | 9 (45%) | 11 (31%) | 0.314 | 77 (22.7%) |
CKD(stage ≥ 3)or ESRD | 1 (6%) | 1 (3%) | 1.000 | 24 (7.1%) |
COPD | 1 (6%) | 1 (3%) | 1.000 | 8 (2.4%) |
Diabetes | 3 (17%) | 8 (25.8%) | 0.701 | 70 (20.6%) |
Medication, n (%) | ||||
β-Blockers | 5 (28%) | 17 (55%) | 0.066 | —— |
ACEI | 5 (28%) | 8 (26%) | 0.880 | —— |
ARBs | 3(17%) | 11 (35.5%) | 0.160 | —— |
Calcium blocker | 5 (28%) | 14 (45%) | 0.368 | —— |
Diuretics | 2 (11%) | 3 (10%) | 0.873 | —— |
Statins | 18 (100%) | 30 (97%) | 1.000 | —— |
Nitrates | 5 (28%) | 8 (26%) | 1.000 | —— |
Antiplatelet drugs | 20 (100%) | 35 (100%) | 1.000 | —— |
Angiographic findings | —— | |||
Numbers of vessels with significant stenosis > 50% | —— | |||
1 | 3 | 6 | 1.000 | —— |
2 | 2 | 2 | 0.974 | —— |
3 | 2 | 2 | 0.623 | —— |
Vessels with stenosis > 50% | —— | |||
LM | 1 | 2 | 1.000 | —— |
LAD | 5 | 6 | 0.744 | —— |
LCX | 5 | 2 | 1.000 | —— |
RCA | 1 | 3 | 1.000 | —— |
Echocardiographic Variables | ||||
Mitral E (cm/s) | 66 ± 2 | 71 ± 2 | 0.143 | 79 ± 1 |
Mitral A (cm/s) | 75 ± 4 | 88 ± 4 | 0.045 | 86 ± 1 |
E/A ratio | 0.8 (0.7—1.0) | 0.8 (0.7—0.9) | 0.383 | 0.9 (0.8—1.1) |
Septal e′ velocity (cm/s) | 6.8 ± 0.5 | 6.3 ± 0.3 | 0.363 | 6.4 ± 0.1 |
Lateral e′ velocity (cm/s) | 10 (7.8—12.0) | 8.0 (6.0—10.4) | 0.144 | 9(6—11) |
E/e’mean ratio | 8.0 (6.8—10.6) | 10 (8.2—11.2) | 0.078 | 10 (8—15) |
TR peak velocity (m/s) | 2.3 (2.1—2.5) | 2.2 (2.1—2.6) | 0.949 | 2.5 (2.3—2.8) |
LVEF (%) | 66 ± 2 | 64 ± 1 | 0.733 | 64 ± 1 |
LAVimax (ml/m2) | 14.6 ± 1.7 | 16.5 ± 1.2 | 0.388 | 32.5 ± 0.7 |
LAEF (%) | 55 ± 2 | 55 ± 2 | 0.851 | 54 ± 1 |
LASr(%) | 32.9 ± 1.5 | 23.2 ± 1.2 | < 0.001 | 27.2 ± 0.5 |
E/LASr ratio | 2.0 (1.8—2.2) | 3.0 (2.6—4.0) | < 0.001 | 2.7 (2.1—3.8) |